Targeting Cancer Survival Genes in Solid Tumors

Episode Summary

Executive Summary: Nuago Therapeutics argues that most cancer drugs fail because tumors adapt to single-target therapies. CEO Robert Schickel describes a short-RNA platform that silences multiple survival genes at once, triggering a multi-pathway cell-death program called DICE. He says cancer cells are selectively vulnerable because they suppress microRNAs, creating both efficacy and a wide therapeutic window, with lead programs in liver, ovarian, and prostate cancer.

Main Topics: Why current oncology therapies fail (Priority: 5/5): Schickel says targeted and cellular therapies often produce temporary benefit but rarely improve long-term overall survival because tumors mutate, reroute survival signaling, or evade treatment. Nuago’s founding and business-science strategy (Priority: 4/5): The company grew from academic work with Marcus Peter’s lab and Schickel’s background in business development, which he says helps align novel biology with market need and reduce development risk. DICE mechanism and survival gene elimination (Priority: 5/5): Nuago’s core concept is to silence multiple survival genes simultaneously, collapsing tumor survival networks and activating multiple cell-death pathways rather than a single apoptotic route. Selectivity, microRNAs, and seed-sequence biology (Priority: 5/5): Schickel claims cancer cells downregulate microRNAs, allowing Nuago’s short RNAs to enter and act on survival genes while sparing healthy tissues; he frames seed-mediated activity as the intended therapeutic feature. Resistance and multi-target durability (Priority: 4/5): Because the platform attacks many genes and pathways at once, Schickel argues tumors have little room to evolve escape mechanisms compared with conventional single-target drugs. Pipeline, lead assets, and delivery strategy (Priority: 4/5): NU001/NU003 are the key assets in ovarian and liver cancer, with NU002 aimed at prostate cancer. Nuago prioritizes indications based on unmet need and uses existing delivery modalities to lower risk. Financing and development plan (Priority: 3/5): The company has combined founders' capital, SAFE funding, a bridge round, and NIH grants, and is seeking additional capital to reach IND-enabling studies and broaden its pipeline.

Key Arguments: Modern targeted and cellular therapies fail most patients over time because tumors adapt, while Nuago is built to hit the fundamental survival system rather than one pathway. DICE works by eliminating multiple survival genes, collapsing interconnected cellular networks and inducing several death pathways simultaneously, making escape much harder for tumors. Cancer cells are supposedly more vulnerable because they globally downregulate microRNAs, which normally protect differentiated healthy cells from aberrant RNA activity. The seed sequence in Nuago’s short RNAs is not an off-target problem but the mechanism of action, modeled on tumor-suppressive microRNAs and designed to silence survival genes. Selectivity is driven by cancer biology, not added chemistry: normal tissues retain microRNA-mediated blockade, while tumors expose the target and the silencing machinery. Multi-gene targeting should reduce resistance because cancers would need to mutate or bypass many unrelated targets at once, which Schickel says is highly improbable. Delivery remains the main practical risk, so Nuago is choosing clinically established delivery systems rather than inventing new ones. The platform is intended to be cancer-agnostic, with final indication choice driven by survival-gene expression and unmet need rather than histologic subtype. Nuago believes aggressive, therapy-resistant tumors may be especially sensitive, but even early lesions and immortalized cells can respond. The company views surgery as still essential, but envisions its RNA therapy as a broad adjunct or standalone treatment across solid tumors and potentially liquid tumors. Schickel argues that the platform’s biology is conserved across species and populations, implying broad global applicability once delivery is solved.

Data Points: Targeted pharmaceutical therapy failure rate: ~90% - Schickel says most targeted therapies eventually fail patients over the last 30 years. Cellular therapy failure rate: ~85% - He contrasts this with the high failure rate of cellular therapies. Cell death pathways: 22 - Schickel says DICE activates multiple molecularly driven cell-death pathways, potentially all 22. Activated death pathways observed: 6 to 8 - He says data suggests six or eight pathways are activated at any one time. Therapeutic window: 1 to 2 orders of magnitude - Nuago claims a wide efficacy window before toxicity, centered in picomolar concentrations. Toxicity threshold above therapeutic window: ~3 additional orders of magnitude - He says much more drug would be needed to trigger toxicity in healthy cells. Seed sequence length: 6 nucleotides - Nuago says this short sequence is key to its microRNA-like targeting behavior. MicroRNA seed family length: 7 to 8 nucleotides - Schickel compares Nuago’s mechanism to endogenous microRNA family targeting. Genes downregulated in one ovarian cancer analysis: 140 genes - He says their sequence downregulated 140 genes at the mRNA/protein level. Proportion of those genes that were survival genes: 40% - Part of the 140-gene ovarian cancer set. Proportion that were oncogenes: 35% - Another major portion of the ovarian cancer target set. Overall share related to oncogenic process: 99.2% - He says 99.2% of targeted genes were directly related to oncogenesis and tumor survival. Target eligibility for current targeted therapies: 7.5% to 15% - Schickel says the field’s biggest recent advance has only doubled the eligible patient pool. Estimated liver cancer deaths in U.S.: ~49,000 to 60,000 annually - He gives a rough annual mortality estimate while discussing liver cancer. Stage 4 liver cancer survival: 6% to 8% - Used to justify liver cancer as a high-unmet-need indication. Stage 1 liver cancer survival: 35% - He contrasts early-stage liver cancer outcomes with advanced disease. Funding from friends and family/SAFE investors: $1.3 million - Early capital raised for the company. Bridge equity round: $1.7 million - Additional early-stage funding. NIH grant funding: $4 million - Non-dilutive support for preclinical development. Near-term fundraising goal: $5 million - Schickel says this would fund the company to the beginning of Q2 next year. Three-year capital need: $25 million - Estimated amount needed over the next three years. Tumor types evaluated: 66 - He says Nuago tested the platform across many tumor types. Species evaluated: 7 - Human plus multiple animal species were mentioned.

Pivotal Quotes: "Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs out, leading to relapse and poor survival." — Daniel Levine (intro): Sets up the central problem Nuago aims to solve. "We believe we're activating all of them at some level." — Robert Schickel: Describing DICE as a multi-pathway cell-death program rather than a single mechanism. "It is the seed sequence that's responsible for the tumor suppression." — Robert Schickel: Explaining why Nuago treats seed-mediated RNA activity as therapeutic rather than undesirable off-targeting.

Implications: If validated clinically, Nuago could shift RNA therapeutics from precision single-target drugs to a broader, multi-gene oncology platform. The biggest hurdles remain delivery, capital, and proving durable human efficacy and safety.